By Editorial TeamThe healthcare AI landscape is awash with innovation, but for investors and policymakers, distinguishing genuine progress from speculative hype remains a critical challenge. Our Transparency Index cuts through the noise, evaluating AI healthcare companies not by their funding rounds or media mentions, but by the accessibility and rigor of their published clinical evidence. This foundational metric, we argue, is the truest predictor of long-term viability and impact.
The Imperative of Evidence: A Deeper Look at Leading AI Healthcare Companies
In an ecosystem where the promise of AI often outpaces its proven utility, the Transparency Index offers a vital counter-narrative. We assert that a company’s commitment to openly publishing its clinical validation in peer-reviewed journals directly correlates with its eventual survival and market penetration. Conversely, companies operating in an opaque evidence vacuum tend to falter. This isn’t merely an academic distinction; it’s a commercial and ethical imperative, especially for AI intended for medical purposes, or SaMD. Consider the varying approaches among prominent players. HeartFlow, a publicly traded company (Nasdaq: HTFL), for instance, has built its reputation on a robust foundation of clinical trials and peer-reviewed publications validating its CT-FFR technology. This commitment to evidence has allowed it to navigate regulatory pathways and gain physician adoption, demonstrating how a strong evidence base can translate into a defensible competitive advantage, or a “patent thicket” as some describe it. HeartFlow’s consistent publication record in high-impact journals supports its claims of clinical utility and accuracy, a stark contrast to some peers. Tempus AI, a publicly traded company (NASDAQ: TEM), while known for its extensive real-world data collection, faces a different challenge: translating that data into broadly accessible and clinically actionable insights with transparent validation. The sheer volume of data does not automatically equate to robust, published evidence of AI model performance or clinical outcomes. Similarly, Flatiron Health, acquired by Roche, has excelled in aggregating oncology data, but its clinical research business was acquired by Paradigm Health in December 2025. The transparency around the clinical validation of specific AI applications built upon this data is what the Transparency Index scrutinizes. The ability to demonstrate how AI insights from these platforms directly improve patient care, through published outcomes, is paramount. On the other end of the spectrum, companies like Babylon Health, which pursued aggressive growth strategies often with less emphasis on transparent, peer-reviewed clinical validation, ultimately ceased operations. Babylon Health filed for Chapter 7 bankruptcy in the US in August 2023, and its UK operations were sold to eMed Healthcare UK in September 2023, effectively winding down the company. Their rapid expansion and broad claims, not always backed by accessible, independent evidence, serve as a cautionary tale for investors. The narrative that opaque companies tend to fail is powerfully illustrated here. Similarly, Olive AI, despite significant investment, struggled to demonstrate consistent, measurable ROI through transparently published clinical or operational efficiencies, leading to substantial restructuring and ultimately shutting down in October 2023 after selling off its core business units. Viz.ai stands out for its focused approach to stroke care, and its regulatory clearances are often accompanied by efforts to publish data supporting its impact on time-to-treatment and patient outcomes. This aligns with the principles of the Transparency Index: clear, verifiable evidence is key. Omada Health, operating in the digital therapeutics space, has also invested in publishing outcomes data for its programs, understanding that payer and provider adoption hinges on demonstrated efficacy. Hims & Hers, primarily a telehealth and direct-to-consumer platform, leverages AI for operational efficiency and personalized recommendations, but the bar for clinical validation for its core offerings differs from diagnostic or therapeutic SaMD. For Hims & Hers, the focus shifts to the clinical efficacy of the underlying treatments and the safety of the telehealth delivery model, requiring a different but equally rigorous form of transparency. As Eric Topol frequently emphasizes, the true value of AI in medicine lies not in its technological sophistication alone, but in its ability to demonstrably improve patient outcomes and clinician workflows, backed by rigorous scientific scrutiny. The absence of such scrutiny, as Casey Ross and Bob Herman have often highlighted in their critical reporting on health tech, can mask fundamental flaws and lead to unsustainable business models.
Regulatory Landscape and the Gold Standard of Evidence
The regulatory environment, particularly the FDA’s Software as a Medical Device (SaMD) Framework, provides a crucial backdrop for understanding the importance of transparency. Devices cleared under this framework, especially those with adaptive algorithms, necessitate a clear understanding of their performance characteristics and how they evolve. The FDA’s emphasis on Good Machine Learning Practice (GMLP) and predetermined change control plans (PCCP) underscores the need for continuous validation and transparent reporting of AI model behavior. For investors, a company’s ability to navigate these regulatory pathways efficiently, often leveraging robust clinical data, indicates a mature and de-risked asset. The gold standard for this validation remains publication in prestigious medical journals such as JAMA, NEJM, and The Lancet. These platforms provide the rigorous peer review necessary to establish credibility and trust among the medical community, payers, and ultimately, patients. Reports from outlets like STAT News frequently dissect the evidence base behind new healthcare AI technologies, often influencing investor and policymaker perceptions. A strong publication record not only validates a company’s claims but also serves as a critical differentiator in a crowded market. JAMA editorial on AI clinical validation
Investing in Verifiable Impact
The Transparency Index is more than a ranking; it’s a framework for strategic investment and responsible policy-making in healthcare AI. For investors and VCs, prioritizing companies with robust, transparently published clinical evidence is not just about de-risking; it’s about identifying those poised for sustainable growth and genuine market leadership. These companies build trust, accelerate adoption, and are better positioned for favorable reimbursement pathways and long-term commercial success. Policymakers, in turn, can leverage this emphasis on transparency to shape regulatory guidelines that promote innovation while safeguarding patient safety and public health. As the field matures, the distinction between AI solutions backed by rigorous, accessible evidence and those built on aspirational claims will become increasingly stark. Our analysis consistently shows that transparency index correlates with company survival; opaque companies tend to fail. The future of healthcare AI belongs to those who can not only innovate but also unequivocally prove the value and safety of their innovations through the most demanding scientific channels. FDA SaMD guidance document NEJM perspective on AI in medicine
Frequently Asked Questions
What is the primary metric the Transparency Index uses to evaluate healthcare AI companies?
The Transparency Index primarily evaluates healthcare AI companies based on the accessibility and rigor of their published clinical evidence. This foundational metric, rather than funding rounds or media mentions, is considered the truest predictor of long-term viability and impact for investors and policymakers.
Why is transparent clinical evidence crucial for the long-term success of healthcare AI companies?
Transparent clinical evidence, especially publication in peer-reviewed journals, directly correlates with a company’s eventual survival and market penetration. It allows companies to navigate regulatory pathways, gain physician adoption, and establishes a defensible competitive advantage, demonstrating the AI’s proven utility and impact on patient outcomes.
How does the Transparency Index differentiate between companies with extensive data versus those with robust evidence?
The Transparency Index scrutinizes the clinical validation of specific AI applications built upon data, not just the volume of data collected. Companies like Tempus AI, despite extensive real-world data, still face the challenge of translating that data into broadly accessible and clinically actionable insights with transparent validation, which is paramount for demonstrating improved patient care through published outcomes.
What are the implications for companies that do not prioritize transparent clinical validation?
Companies that operate in an opaque evidence vacuum or with less emphasis on transparent, peer-reviewed clinical validation tend to falter. Examples like Babylon Health and Olive AI, despite significant investment, ultimately ceased operations or underwent substantial restructuring, serving as cautionary tales for investors due to their inability to demonstrate consistent, measurable ROI through transparently published evidence.
How does the regulatory landscape, particularly the FDA’s SaMD Framework, reinforce the importance of transparent evidence?
The FDA’s SaMD Framework, with its emphasis on Good Machine Learning Practice (GMLP) and predetermined change control plans (PCCP), underscores the need for continuous validation and transparent reporting of AI model behavior. For investors, a company’s ability to navigate these regulatory pathways efficiently, often leveraging robust clinical data, indicates a mature and de-risked asset.
